747 related articles for article (PubMed ID: 17220639)
1. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
2. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).
Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
7. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
9. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
10. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
12. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment.
Nakamura S; Matsumoto T; Suekane H; Nakamura S; Matsumoto H; Esaki M; Yao T; Iida M
Cancer; 2005 Aug; 104(3):532-40. PubMed ID: 15937928
[TBL] [Abstract][Full Text] [Related]
15. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
16. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
18. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
20. [Primary MALT-type lymphoma of the breast].
Rafel M; Esteve J; Cervantes F; Velasco M; Serra A; Campo E; Montserrat E
Sangre (Barc); 1998 Jun; 43(3):244-7. PubMed ID: 9741235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
